Optimizing blood pressure control in multimorbid hypertensive patients: insights from a real-world taiwanese cohort

Shao-Kai Sum1, Yu-Yen Ou2, Yao-Chang Wang3

  • 1Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan.

Journal of Hypertension
|November 11, 2025
PubMed

Insights

Angiotensin II receptor blockers (ARBs) reduce mortality in Taiwanese patients with hypertension and cardiometabolic multimorbidity (CMM). Diuretics and vasodilators may increase risk, while optimal blood pressure control benefits those with CMM.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Current hypertension guidelines recommend ACE inhibitors (ACEi), ARBs, CCBs, and diuretics for patients with cardiometabolic multimorbidity (CMM).
  • The effectiveness of these antihypertensive medications in Asian populations, particularly those with CMM, remains underexplored.

Purpose of the Study:

  • To evaluate the association between different classes of antihypertensive medications and all-cause mortality in Taiwanese patients with hypertension and CMM.
  • To assess the impact of systolic blood pressure (SBP) control and variability on mortality risk in this population.

Main Methods:

  • A population-based cohort study utilizing Taiwan's administrative health databases from 2004 to 2014.
  • Inclusion criteria: patients aged ≥20 years with hypertension and ≥8 outpatient blood pressure measurements.
  • All-cause mortality was analyzed using inverse probability weighted Cox models, examining medication classes, adherence, and SBP control.

Main Results:

  • Angiotensin II receptor blockers (ARBs) were associated with reduced mortality in patients with CMM (HR=0.80).
  • Diuretics (HR=1.63) and vasodilators (HR=1.22) were linked to increased mortality risk; ACE inhibitors and CCBs showed neutral effects.
  • Optimal SBP control (120-139 mmHg) benefited multimorbid patients, whereas intensive control (<120 mmHg) increased risk in less complex cases. High SBP variability also raised mortality risk.

Conclusions:

  • The effectiveness of antihypertensive medications varies significantly based on the burden of cardiometabolic multimorbidity.
  • ARBs demonstrate a mortality-reducing benefit in multimorbid patients, contrasting with potential risks associated with diuretics and vasodilators.
  • Optimal SBP control is crucial for patients with CMM, but intensive blood pressure lowering may pose risks in less complex hypertensive individuals.
Abstract

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
600
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
349
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
452
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
1.3K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
765